ID
23784
Description
Study part: Central Laboratory –Blood Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.
Keywords
Versions (1)
- 7/12/17 7/12/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
July 12, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Central Laboratory –Blood Week 32 Mepolizumab HES NCT00086658
Central Laboratory –Blood Week 32
- StudyEvent: ODM
Similar models
Central Laboratory –Blood Week 32
- StudyEvent: ODM
No comments